WFG Advisors’s Bioverativ Inc. Common Stock BIVV Stock Holding History

WFG Advisors’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-98	Closed	-$5K	–	1732
2017 Q1	$5K	Buy	+98	New	+$4.83K	﹤0.01%	1238

Other funds holding BIVV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

ValueAct Holdings San Francisco, California $5.71B AUM 7.41% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

WFG Advisors's BIVV Position: Q2 2017 in Review

WFG Advisors sold out of Bioverativ Inc. Common Stock (BIVV) in Q2 2017, closing a stake of 98 shares — an estimated $5K sold.

WFG Advisors first reported a position in BIVV in Q1 2017 and held it in 1 quarter. The position peaked at $5K in Q1 2017. 452 funds tracked by Wall St. Rank hold BIVV as of Q2 2017.

WFG Advisors reported no remaining Bioverativ Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
WFG Advisors sold 98 Bioverativ Inc. Common Stock shares in Q2 2017, an estimated $5K.
WFG Advisors first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 1 quarter.
WFG Advisors's Bioverativ Inc. Common Stock position peaked at $5K in Q1 2017.
452 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.